Clostridium perfringens (Veillon and Zuber) Hauduroy et al.
商品貨號
B222053
Strain Designations
LNG11
Application
Produces antineoplastic agents
Isolation
Derived from Clostridium perfringens strain Lechien
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
freeze-dried
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Preceptrol®
no
Type Strain
no
Comments
Type A
The presence of cpa, cpb2, and pfoA genes was confirmed by PCR.
This strain does not produce epsilon toxin
Toxins
This strain does not produce epsilon toxin.
Medium
ATCC® Medium 1053: Reinforced Clostridial medium (Oxoid CM149)
ATCC® Medium 2107: Modified Reinforced Clostridial
ATCC® Medium 260: Trypticase soy agar/broth with defibrinated sheep blood
Growth Conditions
Temperature: 37°C
Atmosphere: Anaerobic
Name of Depositor
JR Lapointe
References
La Pointe JR, Fredette V. Anti-tumor product of bacterial origin. US Patent 3,936,354 dated Feb 3 1976
Lapointe JR, Fredette V. [Nitrosoguanidine-induced attenuated Clostridium perfringens type A mutant in gas gangrene]. Can. J. Microbiol. 21: 1259-1269, 1975. PubMed: 169977
Lapointe JR, Fredette V. [Principle and new media for sporulation of Clostridium perfringens. Preliminary results with an attenuated mutant] Union Med. Can. 104(4): 527-538, 1975. PubMed: 178082
Lapointe JR, Fredette V. [Analysis of the oncolytic properties of Clostridium perfringens. Use of an attenuated mutant and Ehrlich solid carcinoma] Union Med. Can. 104(7): 1070-1077, 1975. PubMed: 169620
